sAC Inhibitors
TDI-11861, TDI-10229
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Not Yet Determined
-
Intended Duration:
- Pericoital
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Weill Cornell Medicine, Sacyl Pharmaceuticals
Details
- API: TDI-11861
- Target: Soluble Adenylyl Cyclase (sAC)
-
Mechanism of Action:
- Inhibition of Sperm Motility
- Inhibition of Sperm Capacitation
- Inactive Materials: Not Yet Determined
- Regimen: On Demand
- MPT: Not Potential MPT
- Promising Attributes: Current pre-clinical work is focused on the development of an on-demand male method
Product Status
Active Pre-Clinical Research
History
2019: Frameshift variant of ADCY10, which encodes for sAC, found to be associated with reduced sperm motility.
2021-2022: Development of prototypes of increasingly potent sAC inhibitors with drug-like properties suitable for use in vivo studies.
2023: Study shows a single dose of a safe, acutely-acting sAC inhibitor with long residence time renders male mice temporarily infertile.
The primary development team has received targeted NIH funding for development of an on-demand nonhormonal male contraceptive using an ADCY10 inhibitor each year from 2023-2025.
Publications
Additional Information
NIH Reporter Record - 5P50HD113015-03
NIH Reporter Record - 1R43HD120055-01